Lonza Holds Grand Opening of New Drug Product Services Labs

News
Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-12-07-2016
Volume 11
Issue 12

The new facility will focus on formulation development, drug product analytical development, and quality control.

Lonza has opened its new drug product services laboratories in the Stücki Science Park Basel. The new 1300-m2 facility will focus on formulation development, drug product analytical development, and quality control.

The grand opening, held on Nov. 2, 2016, was attended by approximately 75 guests and Lonza participants, who had the opportunity to tour the facility and experience a virtual reality journey into the world of drug product development, manufacture, and administration.

Among the dignitaries attending the event was Christoph Brutschin, state councilor, head of the Department of Economic, Social, and Environmental Affairs of the Canton of Basel-Stadt, and president of the Conference of the Cantonal Councilors for the Economy (CCCE).

According to Richard Ridinger, CEO of Lonza, Basel was chosen as a site for Lonza’s first-ever drug product development facility because of its access to the latest technologies and experts in a central location.

Hanns-Christian Mahler will be leading the new drug product service laboratory team. The mission will be to use industry best practices to advance drug product development programs.

In addition to providing services such particle testing or container closure integrity testing to enable safer medicines, the Lonza hub offers services to detect trace impurities in pharmaceutical products, including extractables and leachables from plastics used in manufacturing. All of these services are offered as standalone or as part of a comprehensive drug product development program, comprising formulation, stability, primary packaging, process development, and manufacturing.

Source: Lonza

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes